Amryt Pharma: EIB Funds Secure Phase III For Rare Skin Disease Candidate And Cholesterol Drug License
Executive Summary
Not many 18-month old rare and orphan disease-focused biotech companies have an approved product in their portfolio. Even fewer have persuaded the European Investment Bank to make a direct investment into their business. Amryt Pharma can claim both.
You may also be interested in...
US FDA’s Botanical Drugs Guidance Will See Rare Outing For Amryt’s Filsuvez NDA
Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.
Better Together? Aegerion And QLT Merge To Solve Problems
Aegerion and QLT will unite to create a new company dubbed Novelion in a deal that could help both companies solve some long-standing issues.
New Rare Disease Player Amryt Being Created By Fastnet Reverse Takeover
A new orphan drug player - Amryt Pharma Plc- is coming to the London stock market heralding a promising pipeline and experienced leadership, arriving via a reverse takeover with Alternative Investment Market (AIM)-listed investment firm Fastnet Equity PLC.